Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clortermine is an anorectic drug of the amphetamine class, developed by Ciba in the 1960s for short-term adjunctive treatment of exogenous obesity. It is a sympathomimetic amine and a structural analogue of phentermine, specifically the 2-chloro analogue. Unlike typical amphetamines, clortermine produces very low rates of self-administration in animals and likely does not act primarily on dopamine pathways. Instead, it may function as a serotonin and/or norepinephrine releasing agent to suppress appetite. Its long duration allows for once-daily dosing. Common side effects include insomnia, dry mouth, palpitations, and tachycardia[3][4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clortermine.